Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).

doi:10.1200/JCO.23.02668

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Oct 2024

Pike Luke R G, Miao Emily, Boe Lillian A, Patil Tejas, Imber Brandon S, Myall Nathaniel J, Pollom Erqi L, Hui Caressa, Qu Vera, Langston Jacob, Chiang Veronica, Grant Michael, Goldberg Sarah B, Palmer Joshua D, Prasad Rahul N, Wang Tony J C, Lee Albert, Shu Catherine A, Chen Lanyi Nora, Thomas Nicholas J, Braunstein Steve E, Kavanagh Brian D, Camidge D Ross, Rusthoven Chad G

Abstract excerpt

PURPOSE: Newer-generation tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Aniline Compounds

Share to Carbazoles

Share to Indoles

Share to Piperidines

Share to Radiosurgery

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39047224
DOI: 10.1200/JCO.23.02668
PMCID: PMC11874932

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).PMID 39047224Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

BBB-penetrant tyrosine kinase inhibitor plus intracranial radiotherapy vs BBB-penetrant TKI alone in Asians with EGFR-mutated lung adenocarcinoma and brain metastases.Semantic proximity Read ↗

Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases.Semantic proximity Read ↗

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer.Semantic proximity Read ↗

Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.Semantic proximity Read ↗

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.Semantic proximity Read ↗

EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung CancerSemantic proximity Read ↗

Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.Semantic proximity Read ↗

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.